top of page

Bi-weekly: Thursdays, 11 am EDT/EST, 8 am PT/PST, 4 pm BST/BDT, 5 pm CEST/CET
Some seminars were recorded and accessible for a limited time on our youtube channel.

Upcoming Speakers

HubertHuang_600x600 (1).png

May 30th, 2024

Host: Katherine Donovan / Mikolaj Slabicki

Hubert Huang

Broad Institute

Ubiquitin-specific proximity labeling to detect E3 substrate ubiquitylation.

Hubert Huang is a research scientist at the Broad Institute under the Sellers lab. He obtained a BS in Chemistry from Duke University (2012) and conducted undergraduate research in the laboratories of Professor Michael Fitzgerald and Professor Qiu Wang. Hubert obtained his PhD in Chemical Biology in 2017 from Harvard University under the guidance of Professor Nathanael Gray and Professor Jean Zhao in the development of kinase inhibitors and degraders as cancer therapeutics. In 2019, Hubert joined the laboratory of Professor William R. Sellers at the Broad Institute as a postdoctoral scholar, where he developed a ubiquitin-specific proximity labeling approach (E-STUB) to identify E3 ubiquitin ligase substrates. Hubert’s research interest focuses on elucidating the molecular mechanisms and functions of E3 ubiquitin ligases and targeting them for therapeutic uses. Website:

Rosa Barrio and James D. Sutherland


BioE3 identifies specific substrates of ubiquitin E3 ligases

Rosa Barrio and James D. Sutherland are Principal Investigator/Associate PI at CIC bioGUNE in Bilbao, Spain.  The lab focuses on ubiquitin-like (UbL) modifications in development and disease.  Dr. Barrio received her PhD from the Autonomous University of Madrid (ES) and Dr. Sutherland from Harvard University (MA, USA), both using Drosophila to study ubiquitin and ecdysone response, respectively.  After international postdoctoral stints [Barrio: IMBB-FORTH (Crete, GR), EMBL-Heidelberg (DE), and Autonomous University of Madrid (ES); Sutherland: EMBL-Heidelberg (DE), EMBL-Monterotondo (IT) and Cancer Research UK, London (UK)], they both joined CIC bioGUNE, accredited as a Severo Ochoa Center of Excellence and part of the Basque Research and Technology Alliance ( .  They study rare diseases, e.g. Townes-Brock Syndrome (a ciliopathy-like developmental disorder) and develop biotin-based proteomic tools for querying UbL pathways. Lab website:

Sagar Bhogaraju_Group leader_EMBL Grenoble_007.jpg

Sagar Bhogaraju and Christian Behrends

EMBL / Ludwig-Maximilians-University

A ubiquitin-specific, proximity-based labeling approach for the identification of ubiquitin ligase substrates.


Sagar Bhogaraju Sagar was born in Nizamabad, India and studied biological sciences at the Indian Institute of Technology, Kanpur. He then moved to Munich, Germany to pursue his doctoral studies on eurkaryotic cilium at the Max Planck Institute of Biochemistry. After PhD, Sagar moved to Frankfurt to pursue postdoctoral research in the topic of ubiquitin signaling at the Goethe University, Frankfurt Germany. In 2018, he was appointed Group leader at the European Molecular Biology Laboratory in Grenoble France. Sagar’s research group at EMBL focuses on various topics under the umbrella of ubiquitin signaling in disease and physiology. The research in his group is funded by Agence Nationale de Recherche (ANR), EMBL and EMBO. Bhogaraju group webpage:

Christian Behrends After completing a PhD on chaperones and aggregation-prone proteins in the group of Ulrich Hartl at the Max-Planck-Institute of Biochemistry in 2007, Christian joined the Harper lab at Harvard Medical School as post-doc to work on autophagy. In 2010, Christian started his own group at the Institute of Biochemistry II (IBC2) in the Goethe University in Frankfurt where he continued to explore cellular components that regulate autophagy or that are subject to autophagosomal degradation. During this time, the ubiquitin system gained particular attention. In 2016, Christian became professor at the Medical Faculty of Ludwig-Maximilians-University (LMU) and his group part of the Munich Cluster for Systems Neurology (SyNergy). Behrends group webpage:

Headshot Elisia Villemure.jpg

June 13th, 2024

Host: Mikolaj Slabicki / Zuzanna Kozicka

Elisia Villemure


Monovalent degraders of SMARCA2/A4 (BRM/BRG1) acting through recruitment of FBXO22.

Elisia obtained her Master’s degree in Organic Chemistry and Method Development from the University of Ottawa.  She initiated her career as a Medicinal Chemist in 2008 at Boehringer Ingelheim in Canada.  In 2012, she relocated to California where she joined Theravance Biopharma for a year before being part of Genentech.  At Genentech, she was involved in ion channel programs for neuroscience and immunology indications. She is currently Principal Scientist and supports induced proximity and targeted protein degradation efforts within Small Molecule Drug Discovery.

Kyle Seamon

Revolution Medicines

Remodeling the Surface of the Cellular Chaperone Cyclophilin A with Small Molecules to Target the Active State of Oncogenic RAS

Kyle Seamon is a Senior Scientist and Mechanism of Action Group Leader at Revolution Medicines. He completed a B.S. in Chemical Biology at the University of California at Berkeley before Ph.D. studies with Dr. James Stivers in the department of Pharmacology and Molecules Sciences at Johns Hopkins University School of Medicine. After postdoctoral studies and industry work on high-throughput applications of CRISPR-Cas genome editing technologies, Kyle joined Revolution Medicines in 2020 to advance their pipeline of “tri-complex” inhibitors targeting oncogenic RAS proteins.

bottom of page